Cisplatin (COOP) is one of the most active chemotherapeutic agents but is among the most emetogenic drugs. The emetic side-effects of COOP-containing intraarterial chemotherapy have not been evaluated in a prospective randomized trial and the efficacy of serotonin antagonists in preventing the emesis associated with this method of COOP administration has not been assessed. Methods: CODP 50 mg/m 2 and methotrexate 30 mg/m 2 were administered every 3 weeks through intraarterial catheters placed

more »

... the bilateral internal iliac arteries. Patients were classified into two groups: granisetron treatment group (group G) and no treatment group (group NG) with the first course of chemotherapy, crossing over with the second course. The patients in group G received granisetron 40 IJ.g/kg by intravenous infusion. Results: Although intraarterial COOP administration produced less emesis than intravenous COOP administration, at the same concentration, gastrointestinal toxicity is still the most unpleasant side-effect for patients. Granisetron administration significantly reduced nausea and vomiting during the acute emetic phase (an evaluation of treatment as very effective and effective was made in 89% in group G and 33% in group NG (P < 0.001). Complete control of emesis was achieved in 68 and 18% of patients in groups G and NG, respectively (P < 0.0001). Conclusion: A single prophylactic infusion of granisetron was effective in preventing the nausea and vomiting associated with intraarterial COOP-containing therapy.